Skip to content

Want to stay in the know? Sign up for email updates.

Site Logo
Site Logo
  • What We Do
  • Programs
  • Impact
  • Europe
  • Events
  • Media
Tools & Platforms
Give

Neuroscience

C-Path’s Neuroscience Program unites regulators, pharmaceutical and biotech companies, academics, and patient advocates to advance drug development and create better treatments for people living with Parkinson’s, Alzheimer’s, and rare neurodegenerative diseases.

Critical Path for Alzheimer's Disease

Neuroscience

Critical Path for Parkinson’s

Neuroscience

Critical Path for Rare Neurodegenerative Diseases

Neuroscience Rare and Orphan Diseases

Critical Path to Therapeutics for the Ataxias

Neuroscience Rare and Orphan Diseases

Duchenne Regulatory Science Consortium

Neuroscience Rare and Orphan Diseases Pediatrics

Huntington’s Disease Regulatory Science Consortium

Neuroscience Rare and Orphan Diseases

You can help advance drug development and improve lives.

Support Our Mission
Logo
Charity Navigator Logo
Charity Navigator Seal of Approval
AZ Bio Life Science Member
Charity Nav
  • About
  • Annual Reports
  • C-Path FAQs
  • C-Path Newsletter
  • Donate
  • Employment
  • FDA Acknowledgement
  • Request for Proposals
  • Statement of AI Use
  • Team
  • Training

C-Path Main Office
1840 E River Rd, Suite 100
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456

C-Path Amsterdam
Strawinskylaan 3051, 1077 ZX
Amsterdam, The Netherlands
(By Appointment Only)

Tel: 520.547.3440
E-mail: info@c-path.org
© 2025 Critical Path Institute
  • Data Contribution Agreement GDPR
  • Privacy
  • Policies
  • Terms
  • Site Map
Logo
  • Icon
    All Focus Areas
  • competencies icon
    Core Competencies
  • neuron icon
    Neuroscience
  • icon grid rare and orphan
    Rare and Orphan Diseases
  • heart icon
    Pediatrics
  • tablets icon
    Innovation in Translational Science and Biomarkers
  • icon grid coa
    Clinical Outcome Assessment
  • Prior Efforts
  • All Programs
  • Critical Path for Alzheimer’s Disease
  • Critical Path for Parkinson’s
  • Critical Path for Rare Neurodegenerative Diseases
  • Critical Path to Therapeutics for the Ataxias
  • Duchenne Regulatory Science Consortium
  • Huntington’s Disease Regulatory Science Consortium